newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Announces Termination of Legacy CDMO Contract

Termination results in anticipated cash savings of $33.1 million Removes last of legacy contracts associated with former plasma-derived therapeutics business LAVAL, QC and CAMBRIDGE, ENGLAND, Aug. 25, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NAS